Predictive toxicology using systemic biology and liver microfluidic “on chip” approaches: Application to acetaminophen injury
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
We have analyzed transcriptomic, proteomic and metabolomic profiles of hepatoma cells cultivated inside a microfluidic biochip with or without acetaminophen (APAP). Without APAP, the results show an adaptive cellular response to the microfluidic environment, leading to the induction of anti-oxidative stress and cytoprotective pathways. In presence of APAP, calcium homeostasis perturbation, lipid peroxidation and cell death are observed. These effects can be attributed to APAP metabolism into its highly reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI). That toxicity pathway was confirmed by the detection of GSH-APAP, the large production of 2-hydroxybutyrate and 3-hydroxybutyrate, and methionine, cystine, and histidine consumption in the treated biochips. Those metabolites have been reported as specific biomarkers of hepatotoxicity and glutathione depletion in the literature. In addition, the integration of the metabolomic, transcriptomic and proteomic collected profiles allowed a more complete reconstruction of the APAP injury pathways. To our knowledge, this work is the first example of a global integration of microfluidic biochip data in toxicity assessment. Our results demonstrate the potential of that new approach to predictive toxicology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KEGG for representation and analysis of molecular networks involving diseases and drugs
Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M., & Hirakawa, M. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp896 · Cited by 2,322 · cited 1×
“We identified significantly perturbed metabolic pathways by mapping transcriptomic, proteomic and metabolomic data signatures using the KEGG database (Kanehisa et al., 2010) and Ingenuity canonical pathways (Ingenuity® Systems).”
MethodDumas, M.-E., Barton, R. H., Toye, A., Cloarec, O., Blancher, C., Rothwell, A., Fearnside, J., Tatoud, R., Blanc, V., Lindon, J. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601056103 · Cited by 1,042 · cited 1×
“…(Nicholson et al., 1999; 2002), is a powerful tool for characterizing variations in the concentration of such compounds in biofluids or organs in response to drug treatments (Clayton et al., 2006), but also to pathophysiology (Dumas et al., 2006) or genetic polymorphisms (Dumas et al., 2007).”
Self-citationPharmaco-metabonomic phenotyping and personalized drug treatment
Andrew Clayton, T., Lindon, J. C., Cloarec, O., Antti, H., Charuel, C., Hanton, G., Provost, J.-P., Le Net, J.-L., Baker, D., Walley, R. J., et al. (2006) · Nature · doi:10.1038/nature04648 · Cited by 824 · cited 1×
“…(Nicholson et al., 1999; 2002), is a powerful tool for characterizing variations in the concentration of such compounds in biofluids or organs in response to drug treatments (Clayton et al., 2006), but also to pathophysiology (Dumas et al., 2006) or genetic polymorphisms (Dumas et al., 2007).”
Functional behavior of primary rat liver cells in a three-dimensional perfused microarray bioreactor
Powers, M. J., Janigian, D. M., Wack, K. E., Baker, C. S., Stolz, D. B., & Griffith, L. G. (2002) · Tissue Engineering · doi:10.1089/107632702760184745 · Cited by 234 · cited 2×
“…organs can now take advantage of recent developments in microtechnology to produce systems on a very small scale (Griffith and Naughton 2002; Powers et al., 2002; Sivaraman et al., 2005; Chao et al., 2010; Prot et al., 2011a; Baudoin et al., 2007; Novik et al., 2010; Baudoin et al., 2011).”
Background
Cited by
Identifying drug–target interactions based on graph convolutional network and deep neural network
Zhao, T., Hu, Y., Valsdottir, L. R., Zang, T., & Peng, J. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa044 · Cited by 332
Deng, J., Wei, W., Chen, Z., Lin, B., Zhao, W., Luo, Y., & Zhang, X. (2019) · Micromachines · doi:10.3390/mi10100676 · Cited by 229
Esch, M. B., Ueno, H., Applegate, D. R., & Shuler, M. L. (2016) · Lab on a Chip · doi:10.1039/c6lc00461j · Cited by 222
A critical perspective on 3D liver models for drug metabolism and toxicology studies
Serras, A. S., Rodrigues, J. S., Cipriano, M., Rodrigues, A. V., Oliveira, N. G., & Miranda, J. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626805 · Cited by 138
Integrated heart/cancer on a chip to reproduce the side effects of anti-cancer drugs in vitro
Kamei, K.-I., Kato, Y., Hirai, Y., Ito, S., Satoh, J., Oka, A., Tsuchiya, T., Chen, Y., & Tabata, O. (2017) · RSC Advances · doi:10.1039/c7ra07716e · Cited by 113
Advancing pharmaceutical research: A comprehensive review of cutting-edge tools and technologies
Chen, J., Lin, A., & Luo, P. (2024) · Current Pharmaceutical Analysis · doi:10.1016/j.cpan.2024.11.001 · Cited by 112
Metadata
- Authors
- Prot, J.-M., Bunescu, A., Elena-Herrmann, B., Aninat, C., Snouber, L. C., Griscom, L., Razan, F., Bois, F. Y., Legallais, C., Brochot, C., Corlu, A., Dumas, M. E., & Leclerc, E.
- Venue
- Toxicology and Applied Pharmacology
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 259
- Issue
- 3
- Pages
- 270-280
- ISSN
- 0041-008X (ISSN-L)
- OpenAlex
- W1994377711
- Cited by
- 71
- References
- 4
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.